About
About Huaren Pharmaceutical Co., Ltd
Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and bulk preparations comprising sodium chloride, glucose, glucose and sodium chloride, compound sodium chloride, sodium lactate ringer's, and compound electrolyte injections, as well as sterile water for injection and rinsing liquid products. The company also provides therapeutic infusion, which includes blood volume expander, haemostatic, nervous system, circulatory system, anti-infectives, anti-hepatitis and hepatitis adjuvant drugs, antineoplastic and adjuvant drugs, and glucose metabolism; and rubber stoppers. In addition, it is involved in software development; investment management; and construction. The company was founded in 1998 and is based in Qingdao, China.
Visit company website
5 years, 5 months ago
Huaren Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.
From a valuation standpoint, the stock is 68.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Huaren Pharmaceutical Co., Ltd's total revenue rose by 62.8% to $604M since the same quarter in the previous year.
Its net income has increased by 144.7% to $41M since the same quarter in the previous year.
Finally, its free cash flow fell by 224.4% to $-139M since the same quarter in the previous year.
Based on the above factors, Huaren Pharmaceutical Co., Ltd gets an overall score of 3/5.